Skip to content
Implementing IRM by rotating IRS products with different modes of action 27th September 2022

Indoor residual spraying (IRS) has historically been a powerful malaria vector control intervention. IRS can quickly reduce malaria transmission by reducing adult mosquito vector density and longevity.

The efficacy of IRS for malaria control is threatened by widespread resistance in Anopheline vectors to the limited number of insecticide classes currently approved for public health use. Pyrethroid resistance is present across Africa and resistance to carbamates and organophosphates, which were for many years the only alternative IRS insecticide classes to pyrethroids, is also increasing in Anopheles vector populations. In response to the growing threat of resistance to the efficacy of IRS, the World Health Organization’s (WHO) Global Plan for Insecticide Resistance Management (GPIRM) in Malaria has recommended the use of IRS products containing insecticides with different modes of action in annual rotations.

The use of rotations for IRM relies on the fitness cost that resistance mechanisms have on mosquitoes.  Removing selection pressure exerted by a particular insecticide by switching to alternative insecticide classes will result in the frequency of resistance declining over time. Therefore, IRM based on the rotation of different IRS products will reduce selection pressure for the maintenance of existing insecticide resistance and reduce the speed of development of further resistance. However, implementation of IRS product rotations requires at least three IRS insecticides with different modes of action. This is driving the development of a more diverse portfolio of IRS formulations containing new chemistries which can provide sustained control of insecticide-resistant malaria vector populations.

Broflanilide (TENEBENAL™) is a novel insecticide discovered by Mitsui Chemicals Agro, Inc. (MCAG) which has been formulated as VECTRON™ T500, a wettable powder for IRS. Broflanilide is a meta-diamide insecticide which acts as a non-competitive antagonist of the γ -aminobutyric acid (GABA) receptor of chloride channels of the insect inhibitory nervous system and has been classified by the Insecticide Resistance Action Committee (IRAC) as a GABA-gated chloride channel allosteric modulator (IRAC Group 30). In a collaborative project between MCAG and IVCC, supported by a network of collaborating trials facilities in Africa, the bioefficacy of VECTRON™ T500 has been evaluated in laboratory, experimental hut and community trials. VECTRON™ T500 has demonstrated excellent activity against pyrethroid-resistant strains and populations of Anopheles with residual efficacy of 6 months or more on various wall substrates. These results indicate the potential of VECTRON™ T500 as an addition to the arsenal of IRS products needed to maintain both control of malaria and IRM of malaria-transmitting mosquitoes.

Indoor residual spraying (IRS) is an important topic at this week’s Pan-Africa Mosquito Control Association (PAMCA) Conference, in Rwanda. IVCC team members Graham Small and Janneke Snetselaar will present results on the bioefficacy of VECTRON™ T500 in laboratory, experimental hut and community trials during Parallel Symposium 3: Supporting improved insect resistance management strategies – a new mode of action for Indoor Residual Spray (IRS) programmes (Monday 26th September, 14:00 to 15:30 (GMT+2).


By Graham Small & Janneke Snetselaar
All-Party Parliamentary Group (APPG) visit IVCC – July 2022 22nd July 2022

July 2022

Last week, IVCC was delighted to welcome Catherine West MP, Chair of the All-Party Parliamentary Group (APPG) on Malaria and Neglected Tropical Diseases to Liverpool to meet representatives from IVCC and the Liverpool School of Tropical Medicine (LSTM).

Accompanied by Ian Byrne, MP for Liverpool West Derby and Jeremey Lefroy, founding member of the APPG on Malaria and NTDs and Board member of both LSTM and IVCC, Catherine heard about the innovative vector control pipeline that IVCC is developing and delivering including a new outdoor biting intervention called Attractive Targeted Sugar Bait (ATSB) and BASF’s Interceptor® G2 bed net, a dual-insecticide bed net with an innovative mode of action currently undergoing trials across sub-Saharan Africa. In a recent study published in the Lancet, Interceptor® G2 was able to demonstrate an overall 44% reduction in malaria incidence in children 6 months to 10 years in a random controlled trial conducted in Tanzania, demonstrating the immediate and significant impact innovative tools can have on malaria in endemic countries, particularly against the most vulnerable groups such as young children.

The group also heard about the Access programmes being led by IVCC, such as the NgenIRS programme and the New Nets Project which are helping bring life saving interventions to market at scale and at pace and which are already saved many thousands of lives.

Catherine and guests also visited the Liverpool Insect Testing Establishment (LITE) which supports the testing of insecticide-based products for commercial partners against insecticide-resistant colonies.  LITE maintains a range of insecticide susceptible and resistant colonies of mosquitoes and provides a range of approaches for insecticide efficacy testing. The guests closed the day with a visit to LSTM’s venom unit which houses the largest and most diverse collection of tropical venomous snakes in the UK and leads pioneering research into a universal anti-venom and improvements in the efficacy, affordability and safety of snakebite treatments.

Image: Photo of visit to IVCC by APPG Chair :  Caption of photo;  Catherine West MP (second from left) and Ian Byrne MP (far right) talking to IVCC and LSTM colleagues at the Liverpool Insect Testing Establishment.
Kigali Malaria and Neglected Tropical Diseases Summit – June 2022 22nd July 2022

IVCC was privileged to play its part in the Kigali Malaria and Neglected Tropical Diseases Summit that took place on the fringes of the Commonwealth Heads of Government meeting in June.

Governments, the private sector, and philanthropists pledged to help accelerate the global fight to beat malaria and neglected tropical diseases with commitments totalling more than $4 billion.

These $4 billion commitments come at a time when malaria is rising, driven in part by the growing threat of insecticide resistance which is inhibiting the efficacy of bet nets which, for so long have proven to be the most effective intervention tool, helping to halve malaria deaths since the turn of the century.

New insecticides for bed nets are urgently needed to support best practice insecticide resistance management which will prolong the efficacy of these lifesaving interventions.  In addition, new vector control tools are required to also address the growing threat of outdoor biting.

With the support of philanthropic and government funders and industry partners, IVCC is leading the way in helping to develop and bring to market these innovative vector control tools.

The Summit, hosted by the Rwandan Government, featured keynote speeches from HRH Prince of Wales, His Excellency President Kagame, Melinda French Gates, and World Health Organisation’s Director General, Dr Tedros Ghebreyesus.

Chief Executive Officer Nick Hamon announces retirement 24th June 2022

After 9 years as IVCC’s Chief Executive Officer, Nick Hamon has decided to retire. Nick will step down from his role once the IVCC Board of Trustees has completed its search for Nick’s successor and an appropriate transition period, if required, is completed.

Under Nick’s guidance and leadership, IVCC has grown from a small team of seven with grant income of $10m from a single funder to a full-service Product Development Partnership (PDP) supported by eight key funders and over 30 full-time staff, covering product development and market shaping projects across sub-Saharan Africa and the Indo-Pacific region, securing over $300 million of grant income to further vector control innovation.

Nick Hamon said: “It has been an honour and a privilege to lead IVCC for the last nine years.  Together with the support of our funding and industry partners, IVCC continues to deliver a portfolio of innovative vector control tools and marketing shaping interventions, which has enabled lifesaving products to be delivered at pace and scale to those that need them most.”

“I would like to thank all of my colleagues at IVCC and our partners and other stakeholders across vector control who have helped IVCC play such a pivotal role in the global battle to eradicate malaria.”

Commenting on his retirement, Board of Trustees Chair, Sir Stephen O’Brien said: “Given Nick’s decision to move to his well-earned retirement, the IVCC Board is very grateful that he has agreed to remain fully at the helm of IVCC until his successor is in place, the global search for whom the IVCC Board is now actively pursuing.”

“There will soon come the right moment to recognise and celebrate Nick’s considerable achievements in full; for now, I highlight that through Nick’s leadership IVCC has become established as a world-leading PDP.  I and all my colleagues on the Board and the IVCC team are immensely grateful to Nick for his skill and relentless commitment to IVCC and all it stands for. On behalf of the whole malaria community, I would like to express my sincere thanks for his leadership of IVCC, which has significantly contributed towards saving thousands of lives, something which, modest as he is, Nick should justifiably be extremely proud of.”

Tech Update Summer 2022 22nd June 2022

Download the Tech Updates highlighting vector biology and control news, publications and resources.

Given the breadth of vector control-related literature, we are unable to include all relevant work. These updates are intended to focus primarily on Anopheles biology and a subset of control topics with global relevance. Any views expressed in the updates do not necessarily reflect the views or opinions of IVCC. In many cases, we directly quote sections of published work. Mention of trade names or commercial products is solely for the purpose of providing specific information and does not imply recommendation or endorsement by IVCC or its funders.

Sign up to receive the IVCC Newsletter